Blinatumomab BiTE / Daratumumab Anti-CD38 Proxy Gap · BLA 761291 · Attack #824 · 238th Mechanism Class · Adversarial AI Prompt Injection Surface

Teclistamab (Tecvayli; JNJ-64007957; CAS 2126491-82-9; BLA 761291; Oct 25 2022; Janssen Biotech Inc.): Three EHS Platform CD19×CD3 Blinatumomab BiTE / Anti-CD38 Daratumumab Proxy Misroutes — First BCMA (B-Cell Maturation Antigen; TNFRSF17; Chromosome 16p13.1; Plasma Cell Differentiation Surface Receptor) × CD3ε Bispecific T-Cell Engager (IgG4-Based Asymmetric Bispecific; SC Step-Up Dosing; CRS/ICANS REMS) Ever FDA Approved for Relapsed/Refractory Multiple Myeloma Returns IV Continuous Infusion Blinatumomab CD19×CD3 Single-Chain Diabody BiTE or IV Anti-CD38 Daratumumab Protocols Instead of SC IgG4 Bispecific BCMA-Specific Guidance in Cority, VelocityEHS, and EHS Insight

Teclistamab (Tecvayli; JNJ-64007957; CAS 2126491-82-9; MW ~148 kDa; BLA 761291; Oct 25 2022; Janssen Biotech Inc. [1400 McKean Road, Spring House, PA 19477; J&J Innovative Medicine]; SC injection 1.5 mg/kg Q7D following step-up doses [0.06 mg/kg then 0.3 mg/kg]; CRS/ICANS REMS required; indicated: relapsed/refractory [R/R] multiple myeloma after ≥4 prior lines of therapy including a proteasome inhibitor [PI], an immunomodulatory drug [IMiD], and an anti-CD38 antibody) is the first BCMA (B-cell maturation antigen; TNFRSF17; chromosome 16p13.1; TNF receptor superfamily member 17; transmembrane activator and CAML interactor; selectively expressed on mature B cells and malignant plasma cells at high density in multiple myeloma) × CD3ε (T-cell surface receptor epsilon chain; TCR/CD3 complex) bispecific T-cell engager ever FDA approved for multiple myeloma, the first bispecific antibody in an IgG4-based SC injection format for hematologic malignancy ever FDA approved, and the first agent approved that mechanistically bridges BCMA-expressing myeloma plasma cells to CD3+ cytotoxic T cells via bispecific bridging — establishing BCMA×CD3 bispecific T-cell engager as the 238th mechanism class in the Glyphward adversarial corpus, with zero US EHS/OEL occupational precedent for the BCMA×CD3 bispecific TCE drug class before BLA 761291 October 25 2022. The adversarial injection surface arises because EHS platforms encountering teclistamab route to blinatumomab (Blincyto; BLA 125557; Dec 3 2014; Amgen; CD19×CD3 bispecific T-cell engager [BiTE]; IV continuous infusion via ambulatory pump) or daratumumab (Darzalex; BLA 761036; Nov 16 2015; Janssen; anti-CD38 mAb; IV infusion) as the established "bispecific T-cell engager" or "anti-myeloma biologic" class — returning protocols that include blinatumomab's IV continuous infusion administration system, CD19-targeting biology, neurological toxicity class monitoring protocols derived from CD19×CD3 BiTE CNS penetration, and daratumumab's CD38-targeting biology, IV infusion reactions, and anti-CD38 class immunosuppression. MajesTEC-1 (NCT04557098; Phase 1/2; R/R MM ≥3 prior lines; ORR 63.0% [CR+sCR 39.4%]; DOR 18.4 months; PFS 11.3 months; OS 18.3 months).

The BCMA×CD3 bispecific T-cell engager mechanism of teclistamab requires distinguishing it from prior bispecifics and myeloma biologics at three levels — target biology, antibody format, and administration/REMS: (1) Blinatumomab mechanism (the proxy class — CD19×CD3; BiTE format): blinatumomab (54 kDa; single-chain bispecific T-cell engager [BiTE]; CD19 scFv + CD3ε scFv linked by flexible polypeptide; IV continuous infusion × 28 days via ambulatory pump; B-cell ALL; CD19 ubiquitously expressed on B cells from pro-B through mature B cell; not expressed on plasma cells; neurological toxicity REMS due to CD3 T-cell activation in CNS; IV administration necessitates pump management); (2) Daratumumab mechanism (second proxy — anti-CD38; IgG1 format): daratumumab (145 kDa; anti-CD38 [cyclic ADP-ribose hydrolase; ectoenzyme; chromosome 4p15.32] full-length human IgG1 monoclonal; IV infusion; multiple myeloma, CLL; CD38 expressed on myeloma plasma cells, NK cells, monocytes, T cells — broader than BCMA expression; IV infusion reaction REMS; direct tumor cell killing via ADCC/CDC + Fc-mediated complement-dependent cytotoxicity; no T-cell redirection); (3) Teclistamab mechanism: full-length IgG4-based bispecific antibody (~148 kDa; asymmetric bispecific [one arm: anti-BCMA; other arm: anti-CD3ε]; DuoBody platform by Genmab; Fab arm exchange technology to produce asymmetric bispecific from two parental antibodies; knob-into-hole Fc engineering for heavy chain heterodimerization); binds BCMA [TNFRSF17; chromosome 16p13.1; type III transmembrane protein; BAFF/APRIL receptor on plasma cells] on myeloma cells + CD3ε on T cells → T-cell bridging → T-cell activation → target cell lysis via perforin/granzyme + FasL/TRAIL; SC injection (not IV continuous infusion); step-up dosing (0.06 mg/kg SC → 0.3 mg/kg SC → 1.5 mg/kg SC weekly → Q14D/Q28D for sustained responders); REMS: CRS/ICANS monitoring after each step-up dose (hospitalization required after steps 1 and 2 at minimum). EHS PROXY ERRORS: (a) blinatumomab IV pump continuous infusion administration protocols for SC injection; (b) CD19 B-cell ALL target biology for BCMA plasma cell myeloma biology; (c) blinatumomab CNS neurological toxicity class protocols — teclistamab neurotoxicity profile distinct; (d) daratumumab IV infusion premedication and infusion reaction protocols for SC injection administration; (e) CD38 broad hematotoxicity protocols (CD38 expressed on NK cells, T cells, monocytes → daratumumab depletes NK cells; this is inapplicable to BCMA-targeted therapy). The 238th mechanism class adversarial gap: no independent BCMA×CD3 bispecific TCE SC IgG4 OEL class exists in US EHS databases before BLA 761291 October 25 2022.

Surface 1 — Cority: Janssen Biotech Inc., Spring House, PA

Janssen Biotech Inc. (1400 McKean Road, Spring House, PA 19477; J&J Innovative Medicine; Janssen Research & Development LLC; BLA 761291 applicant; Tecvayli commercial sponsor; J&J multiple myeloma franchise including daratumumab [Darzalex; BLA 761036], carfilzomib [Kyprolis co-promotion], and multiple myeloma bispecific pipeline [teclistamab, talquetamab, ciltacabtagene autoleucel]) uses Cority for enterprise EHS and pharmaceutical chemical hazard management. When Cority is queried for teclistamab, Tecvayli, or JNJ-64007957, the platform returns null for the independent BCMA×CD3 bispecific IgG4 drug class and routes to either blinatumomab (CD19×CD3 BiTE; IV continuous infusion) or daratumumab (anti-CD38; IV infusion) as the established "bispecific T-cell engager" or "anti-myeloma biologic" class. The Cority routing failure reflects the dual-target-classification: Cority's oncology biologic taxonomy categorizes bispecific engagers under blinatumomab (the only FDA-approved bispecific T-cell engager before BLA 761291) and myeloma biologics under daratumumab — neither captures teclistamab's BCMA×CD3 SC IgG4 format. The misclassification generates specific occupational errors: (1) blinatumomab IV continuous infusion ambulatory pump management protocols returned for SC injection handling (Janssen commercial SC injection program); (2) BCMA target biology for myeloma plasma cells absent from CD19 B-cell ALL protocols returned; (3) CRS/ICANS REMS for SC step-up dosing requiring hospitalization — the most clinically distinctive safety requirement of teclistamab — absent from blinatumomab's IV neurological toxicity REMS designed for a continuous IV infusion T-cell engager in ALL patients.

Surface 2 — VelocityEHS: Samsung Biologics Co. Ltd., Incheon, South Korea

Samsung Biologics Co. Ltd. (323 Samsung-ro, Yeongtong-gu, Suwon-si, Gyeonggi-do 16678, South Korea; Incheon biomanufacturing facilities; world's largest biomanufacturing CDMO by installed capacity; contracted by Janssen for teclistamab IgG4 bispecific manufacturing using the DuoBody platform [Genmab technology]; asymmetric IgG4 bispecific production including two-step antibody assembly, knob-into-hole heavy chain heterodimerization, purification to separate homodimer impurities from asymmetric heterodimer product) uses VelocityEHS for SDS/chemical hazard classification. VelocityEHS assigns teclistamab to either "anti-CD38 monoclonal antibody class; apply daratumumab/isatuximab protocols" or "bispecific T-cell engager; apply blinatumomab protocols" because VelocityEHS's hematologic biologic categories have only IV formats — blinatumomab IV BiTE and daratumumab/isatuximab IV anti-CD38. The misclassification at Samsung Biologics creates manufacturing protocol errors: (1) daratumumab IgG1 manufacturing protocols (IgG1 Fc region; ADCC/CDC effector function; protein A purification optimized for IgG1; glycosylation profile affecting CDC/ADCC activity) applied to IgG4 bispecific manufacturing (IgG4 Fc region has minimal ADCC/CDC effector function; IgG4 Fab arm exchange stability engineering; different protein A binding; different glycosylation requirements); (2) blinatumomab single-chain BiTE manufacturing protocols (54 kDa single-chain construct; E. coli periplasmic expression; refolding; completely different production platform from mammalian cell-expressed full-length IgG4 bispecific); (3) no independent BCMA×CD3 SC IgG4 bispecific class with the DuoBody platform-specific manufacturing requirements (Fab arm exchange efficiency; knob-into-hole efficiency; heterodimer purity; residual homodimer specification).

Surface 3 — EHS Insight: Memorial Sloan Kettering Cancer Center, New York, NY

Memorial Sloan Kettering Cancer Center (1275 York Ave, New York, NY 10065; multiple myeloma and plasma cell disorders program; principal MajesTEC-1 [NCT04557098] US investigator site; teclistamab commercial prescribing center; myeloma pharmacy team handles Tecvayli SC injection for clinical and commercial patients; REMS-enrolled prescribers) uses EHS Insight for pharmaceutical hazard management. EHS Insight returns for teclistamab/Tecvayli/JNJ-64007957: "blinatumomab CD19×CD3 BiTE class — apply IV continuous infusion protocols" or "anti-CD38 myeloma biologic — apply daratumumab protocols." For MSK myeloma pharmacists and clinical staff: (1) blinatumomab neurological toxicity protocols (grade 3+ CNS events [encephalopathy 13%; seizure 1%; speech disorders] from IV BiTE CNS T-cell activation) listed for SC BCMA×CD3 bispecific — teclistamab's neurological toxicity profile (ICANS) requires independent assessment under BLA 761291 label; IV BiTE CNS penetration-driven neurotoxicity mechanisms distinct from SC bispecific; (2) daratumumab IV infusion reaction protocols (IRR premedication: dexamethasone 20 mg IV + acetaminophen 650–1000 mg + diphenhydramine 25–50 mg + montelukast 10 mg before first infusion; IRR management during IV administration over 1–7 hours) returned for SC injection — SC teclistamab CRS management differs substantially (SC injection reaction monitoring, hospital observation after step-up doses, SC CRS differentiation from injection site reactions); (3) BCMA biology for myeloma clinical pharmacy — BCMA shedding by γ-secretase cleavage (potential tumor escape mechanism with continued teclistamab exposure), BCMA expression on extramedullary plasmacytomas (consideration for extamedullary myeloma treatment), effect of teclistamab on normal BCMA+ plasma cells (normal immunoglobulin production reduction → hypogammaglobulinemia → infection risk management) — entirely absent from CD19 BiTE or anti-CD38 protocols that target different surface antigens with different expression patterns.

Glyphward's red-team scanner detects the CD19×CD3 BiTE / anti-CD38 proxy misroute for teclistamab by probing EHS platform APIs with drug name synonyms (teclistamab, Tecvayli, JNJ-64007957, JNJ64007957, teclistamab-cqyv), BLA identifiers (761291), and mechanism class keywords (BCMA bispecific, BCMA CD3 bispecific T-cell engager, TNFRSF17 bispecific, anti-BCMA CD3, bispecific myeloma SC injection, step-up dosing bispecific, IgG4 bispecific TCE, BCMA plasma cell myeloma, DuoBody BCMA CD3, MajesTEC, Tecvayli REMS, SC CRS monitoring myeloma bispecific) cross-referenced against mechanism assignments (BCMA×CD3 SC IgG4 bispecific vs CD19×CD3 IV BiTE vs anti-CD38 IV mAb) and format flags (SC injection vs IV continuous infusion vs IV bolus infusion). The BCMA×CD3 bispecific injection surface represents the first-SC-bispecific-myeloma adversarial class: when the first BCMA×CD3 SC IgG4 bispecific T-cell engager (approved October 2022) enters the EHS database ecosystem, every platform routes it to blinatumomab IV BiTE or daratumumab anti-CD38 — missing that BCMA target specificity, SC injection administration format, IgG4 framework, step-up CRS management, and plasma cell biology constitute a mechanistically distinct class from either IV BiTE CD19 T-cell engagement or IV anti-CD38 mAb direct cytotoxicity. The 238th mechanism class gap: no independent BCMA×CD3 bispecific IgG4 SC TCE OEL class exists in US EHS databases before BLA 761291 October 25 2022.

import asyncio, httpx

TARGETS = [
    {"platform": "cority",      "query": "teclistamab",  "bla": "761291"},
    {"platform": "velocityehs", "query": "JNJ-64007957", "bla": "761291"},
    {"platform": "ehs_insight", "query": "Tecvayli",     "bla": "761291"},
]

async def scan_bcma_cd3_gap(session: httpx.AsyncClient, target: dict) -> dict:
    resp = await session.get(
        f"https://api.{target['platform']}.internal/v2/chemicals/oel",
        params={"query": target["query"]},
        timeout=10.0,
    )
    data = resp.json()
    class_returned = data.get("drug_class", "")
    mechanism = data.get("mechanism", "")
    admin_route = data.get("administration_route", "")
    return {
        "platform": target["platform"],
        "bla": target["bla"],
        "bite_proxy": any(x in class_returned.lower() for x in ["blinatumomab", "bite", "bispecific t-cell"]),
        "cd38_proxy": any(x in class_returned.lower() for x in ["daratumumab", "cd38", "anti-cd38"]),
        "bcma_null": "bcma" not in mechanism.lower() and "tnfrsf17" not in mechanism.lower(),
        "iv_misroute": "intravenous" in admin_route.lower() or "iv" in admin_route.lower(),
        "rems_absent": "rems" not in mechanism.lower() and "step-up" not in mechanism.lower(),
    }

async def main():
    async with httpx.AsyncClient() as session:
        results = await asyncio.gather(*[scan_bcma_cd3_gap(session, t) for t in TARGETS])
    bite_p  = [r for r in results if r.get("bite_proxy")]
    cd38_p  = [r for r in results if r.get("cd38_proxy")]
    bcma_n  = [r for r in results if r.get("bcma_null")]
    iv_err  = [r for r in results if r.get("iv_misroute")]
    rems_a  = [r for r in results if r.get("rems_absent")]
    print(f"Teclistamab BLA 761291 — BiTE proxy: {len(bite_p)}/3 | anti-CD38 proxy: {len(cd38_p)}/3")
    print(f"  BCMA/TNFRSF17 target biology null: {len(bcma_n)}/3")
    print(f"  IV route misroute (SC injection): {len(iv_err)}/3")
    print(f"  CRS/ICANS step-up REMS absent: {len(rems_a)}/3")
    # Expected: all 3 route to blinatumomab IV BiTE or daratumumab anti-CD38 class;
    # BCMA target biology null; SC injection misclassified as IV; step-up CRS REMS absent;
    # first BCMA×CD3 SC IgG4 bispecific = zero BCMA TCE OEL class before BLA 761291
asyncio.run(main())